New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
13:26 EDTAGN, SPPISpectrum regaining rights to bladder cancer drug not a positive, The Street says
Allergan (AGN) returning the rights to bladder cancer drug apaziquone back to Spectrum Pharmaceuticals (SPPI) is not a positive for Spectrum, contends The Street's Adam Feuerstein. Feuerstein says that Spectrum will need to conduct an additional phase III study of the drug and that the company is going to file for FDA approval based on two, separate studies that each failed to hit their primary endpoints with statistical significance. The Fly notes that Spectrum shares are up about 6.9% to $12.75 in early afternoon trading. Reference Link
News For SPPI;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
16:14 EDTAGNPershing Square liquidates stake in Allergan
Subscribe for More Information
09:03 EDTAGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 17, 2015
09:13 EDTAGNActavis says Allergan CEO not joining combined company board
Subscribe for More Information
08:58 EDTAGNActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTAGNActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTAGNActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTAGNActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information
March 16, 2015
18:38 EDTAGNAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
Subscribe for More Information
17:19 EDTAGNAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
10:22 EDTAGNEuropean Commission clears Actavis' pending acquisition of Allergan
Subscribe for More Information
10:14 EDTAGNOptions with decreasing implied volatility
Options with decreasing implied volatility: EXPR ULTA SGMS QIHU BKS PAY URBN AGN AGNC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use